Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study
Dominique P. Germain(Assistance Publique – Hôpitaux de Paris), Christopher Viereck(Université Paris-Saclay), Laura Barisoni(Duke University), Elfrida R. Benjamin(Université Paris-Saclay), Kathy Nicholls(Melbourne Health), J. Charles Jennette(University of North Carolina at Chapel Hill), Nina Skuban(Université Paris-Saclay), Daniel G. Bichet(Hôpital du Sacré-Cœur de Montréal), Roberto Giugliani(Universidade Federal do Rio Grande do Sul), Jeffrey P. Castelli(Amicus Therapeutics (United States)), Derralynn Hughes(Royal Free London NHS Foundation Trust), Jay Barth(Université Paris-Saclay), Robert B. Colvin(Harvard University)
Cited by 96
Related Papers
The Banff 97 working classification of renal allograft pathology
|Kidney International|1999|3.1k
Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions
|American Journal of Transplantation|2008|1.9k
Reactivity of a monoclonal antibody with human ovarian carcinoma.
|Journal of Clinical Investigation|1981|1.7k
International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology
|Kidney International|1993|1.5k
Banff 2013 Meeting Report: Inclusion of C4d-Negative Antibody-Mediated Rejection and Antibody-Associated Arterial Lesions
|American Journal of Transplantation|2014|1.3k